Pittenger & Anderson Inc. lifted its holdings in Medtronic plc (NYSE:MDT – Get Rating) by 7.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,116 shares of the medical technology company’s stock after purchasing an additional 2,748 shares during the quarter. Pittenger & Anderson Inc.’s holdings in Medtronic were worth $3,943,000 as of its most recent SEC filing.
Other institutional investors have also bought and sold shares of the company. Dixon Hughes Goodman Wealth Advisors LLC purchased a new position in Medtronic in the 4th quarter worth $25,000. PYA Waltman Capital LLC purchased a new position in Medtronic in the 4th quarter worth $25,000. Horan Securities Inc. purchased a new position in Medtronic in the 4th quarter worth $25,000. Ibex Wealth Advisors purchased a new position in Medtronic in the 3rd quarter worth $26,000. Finally, MD Financial Management Inc. raised its stake in Medtronic by 100.0% in the 3rd quarter. MD Financial Management Inc. now owns 210 shares of the medical technology company’s stock worth $26,000 after acquiring an additional 105 shares during the last quarter. 80.23% of the stock is owned by hedge funds and other institutional investors.
In related news, SVP Carol A. Surface sold 6,000 shares of the business’s stock in a transaction on Friday, March 11th. The shares were sold at an average price of $105.30, for a total transaction of $631,800.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Karen L. Parkhill sold 682 shares of the business’s stock in a transaction on Friday, March 18th. The stock was sold at an average price of $110.00, for a total transaction of $75,020.00. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by corporate insiders.
Shares of Medtronic stock traded up $0.46 on Thursday, hitting $101.11. 229,401 shares of the company were exchanged, compared to its average volume of 6,380,778. The stock has a market capitalization of $135.64 billion, a price-to-earnings ratio of 27.53, a price-to-earnings-growth ratio of 2.36 and a beta of 0.74. The company has a 50-day moving average price of $107.77 and a 200 day moving average price of $108.60. Medtronic plc has a 1-year low of $98.38 and a 1-year high of $135.89. The company has a quick ratio of 2.10, a current ratio of 2.61 and a debt-to-equity ratio of 0.46.
Medtronic (NYSE:MDT – Get Rating) last issued its earnings results on Tuesday, February 22nd. The medical technology company reported $1.37 earnings per share for the quarter, topping the consensus estimate of $1.36 by $0.01. Medtronic had a return on equity of 14.57% and a net margin of 15.46%. The business had revenue of $7.76 billion for the quarter, compared to analysts’ expectations of $7.91 billion. During the same period in the previous year, the firm posted $1.29 EPS. The business’s revenue for the quarter was down .2% compared to the same quarter last year. Research analysts forecast that Medtronic plc will post 5.66 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, April 22nd. Stockholders of record on Friday, March 25th were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.49%. The ex-dividend date was Thursday, March 24th. Medtronic’s dividend payout ratio is currently 69.42%.
Medtronic Company Profile (Get Rating)
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software.
- Get a free copy of the StockNews.com research report on Medtronic (MDT)
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
- The S&P 500 Could Fall Another 28%
- Corning Stock is a Technology Value Play
- Wolverine Worldwide Is Ready To Rebound
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.